Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21407274 | 0.87 | HDAC6 (0.56) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL22074652 | 0.83 | HDAC6 (0.58) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21407323 | 0.81 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL29393719 | 0.81 | HDAC6 (0.58) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL29393718 | 0.81 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL21407348 | 0.81 | HDAC6 (0.58) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL24071223 | 0.80 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL21407378 | 0.79 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21407164 | 0.78 | HDAC6 (0.57) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL22074638 | 0.78 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-03-01 | — | — | US | disclosed |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | HDAC6 610/4885HDAC1 551/4885HDAC8 1766/4885 |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | HDAC6 592/4885HDAC1 580/4885HDAC8 1774/4885 |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | HDAC6 592/4885HDAC1 580/4885HDAC8 1774/4885 |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | HDAC6 610/4885HDAC1 551/4885HDAC8 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.